| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 01/09/2002 | EP1169052A2 Angiogenic growth factors for treatment of peripheral neuropathy |
| 01/09/2002 | EP1169046A1 Pulmonary delivery of protonated/acidified nucleic acids |
| 01/09/2002 | EP1168923A1 Dna vaccination for treatment of autoimmune disease |
| 01/09/2002 | EP1168919A2 Low adenosine anti-sense oligonucleotide, compositions, kit and method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) and surfactant depletion |
| 01/09/2002 | EP1168918A1 Vaccines and gene therapy compositions and methods of making and using the same |
| 01/09/2002 | EP1168917A2 Human lung cancer associated gene sequences and polypeptides |
| 01/09/2002 | EP0984699A4 Method of inhibiting immune system destruction of transplanted viable cells |
| 01/09/2002 | EP0789764B1 A novel family of protease inhibitors, and other biologic active substances |
| 01/09/2002 | CN1330715A Selectively replicating viral vectors |
| 01/09/2002 | CN1330714A Virulence genes and proteins and their use |
| 01/09/2002 | CN1330713A Zinc finger binding domains for GNN |
| 01/09/2002 | CN1330557A In situ injection of antigen-presenting cells with generatically enhanced cytokine expression cell factor |
| 01/08/2002 | US6337321 Treaatment of cardiovascular disorders in mammals |
| 01/08/2002 | US6337214 Detection of DNA, RNA and proteins using a test column with two snares |
| 01/08/2002 | US6337209 Molecular constructs containing a carcinoembryonic antigen regulatory sequence |
| 01/08/2002 | US6337192 A synthetic nucleic acid encoding a tumor suppressor protein; therapy for breast cancer, kidney cancers, skin disorders, vascular malformations and intestinal polyps |
| 01/08/2002 | US6337187 An isolated nucleic acid molecule; diagnosis and therapy for obesity, hypertriglyceridemia, and atherosclerosis |
| 01/08/2002 | CA2165821C Antisense oligonucleotides and therapeutic use thereof in human immunodeficiency virus infection |
| 01/08/2002 | CA2148138C Biological factors and neural stem cells |
| 01/03/2002 | WO2002000914A2 Bioengineered vehicles for targeted nucleic acid delivery |
| 01/03/2002 | WO2002000906A2 Replication deficient adenoviral tnf vector |
| 01/03/2002 | WO2002000877A2 Antisense oligonucleotides to inhibit angiogenesis and/or metastasis |
| 01/03/2002 | WO2002000871A2 Method for introducing nucleic acids and other biologically active molecules into the nucleus of higher eukaryotic cells by means of an electrical current |
| 01/03/2002 | WO2002000870A2 Method for transfecting cells using a magnetic field |
| 01/03/2002 | WO2002000862A2 32447, a novel human acyltransferase and uses thereof |
| 01/03/2002 | WO2002000730A2 Pd-l2 molecules: novel pd-1 ligands and uses therefor |
| 01/03/2002 | WO2002000725A2 G-protein coupled receptor org10 |
| 01/03/2002 | WO2002000711A2 Ev-vegf nucleic acids and polypeptides and methods of use |
| 01/03/2002 | WO2002000699A1 Regulation of human rta-like g protein-coupled receptor |
| 01/03/2002 | WO2002000692A2 Pd-l2 molecules: pd-1 ligands and uses therefor |
| 01/03/2002 | WO2002000691A2 Polynucleotides and polypeptides encoded thereby |
| 01/03/2002 | WO2002000690A2 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| 01/03/2002 | WO2002000689A2 HUMAN G PROTEIN-COUPLED RECEPTOR IGPcR11, AND USES THEREOF |
| 01/03/2002 | WO2002000680A2 Cationic steroid derivatives for gene delivery |
| 01/03/2002 | WO2002000264A1 Virus vector for transferring gene into renal cells |
| 01/03/2002 | WO2002000262A2 Modulation of chromosome function by chromatin remodeling agents |
| 01/03/2002 | WO2002000258A1 Medicinal compositions for angiogenic therapy |
| 01/03/2002 | WO2002000250A2 Hiv-1 vaccines and screening methods therefor |
| 01/03/2002 | WO2002000248A2 Use of urokinase inhibitors for the treatment and/or prevention of pulmonary hypertension and/or cardiac remodelling |
| 01/03/2002 | WO2002000242A2 Human papilloma virus treatment |
| 01/03/2002 | WO2002000232A2 Methods and compositions for developing spore display systems for medicinal and industrial applications |
| 01/03/2002 | WO2002000210A2 Use of agents capable of reducing uric acid levels for the treatment of cardiovascular disease |
| 01/03/2002 | WO2002000194A2 Polymeric micelle compositions |
| 01/03/2002 | WO2002000174A2 Compositions and methods for the therapy and diagnosis of lung cancer |
| 01/03/2002 | WO2002000024A1 New strategy for leukemia therapy |
| 01/03/2002 | WO2002000017A2 Erk-5 deficient animals and methods of inhibiting angiogenesis through the inhibition of erk-5 |
| 01/03/2002 | WO2001071005A3 Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| 01/03/2002 | WO2001070810A3 Atp binding cassette transporter 1 (abc1) gene polymorphisms and uses thereof for the diagnosis and treatment of lipid disorders, cardiovascular diseases and inflammatory diseases |
| 01/03/2002 | WO2001064880A3 Human dynamin 40322 |
| 01/03/2002 | WO2001057086A3 Novel human g protein coupled receptor proteins and polynucleotides encoding the same |
| 01/03/2002 | WO2001055336A3 Methods and materials relating to cd84-like polypeptides and polynucleotides |
| 01/03/2002 | WO2001053344A3 Chondromodulin-i related peptide |
| 01/03/2002 | WO2001051083A3 Innate immunity-stimulating compositions of cpg and saponin and methods thereof |
| 01/03/2002 | WO2001046383A3 Compositions and methods involving an essential staphylococcus aureus gene and its encoded protein |
| 01/03/2002 | WO2001042297A3 Clasp-3 transmembrane protein |
| 01/03/2002 | WO2001041813A3 Methods of treating lupus based on antibody affinity and screening methods and compositions for use thereof |
| 01/03/2002 | WO2001037853A9 Methods and agents for the inhibition of smooth muscle cell proliferation |
| 01/03/2002 | WO2001036460A3 Methods and means for regulation of gene expression |
| 01/03/2002 | WO2001035935A3 Inhibitors of endo-exonuclease activity such as pentamidine for the treatment of cancer |
| 01/03/2002 | WO2001032843A3 Enhanced immune recognition of pathogenic cells by icsbp expression |
| 01/03/2002 | WO2001027334A3 Methods and compositions for correlating ccr5 expression with essential hypertension |
| 01/03/2002 | US20020002272 Eliciting HCV-specific antibodies |
| 01/03/2002 | US20020002269 Artemin, a neurotrophic factor |
| 01/03/2002 | US20020002143 AIDS virus vaccines using sendai virus vector |
| 01/03/2002 | US20020002142 Method for identifying and using A2B adenosine receptor antagonists to mediate mammalian cell proliferation |
| 01/03/2002 | US20020002131 Providing exogenous antiangiogenic protein to endothelial cells associated with said tissue |
| 01/03/2002 | US20020001842 Cytoplasmic transfer to de-differentiate recipient cells |
| 01/03/2002 | US20020001806 Nucleotide sequences coding enzymatic polypeptde for use in the prevention of apoptosis; neuroprotective agents; antitumor agents |
| 01/03/2002 | US20020001629 Pretreatment; inducing stress response |
| 01/03/2002 | US20020001612 Methods of forming protein-linked lipidic microparticles, and compositions thereof |
| 01/03/2002 | US20020001583 Zace1: a human metalloenzyme |
| 01/03/2002 | US20020001581 Introducing a recombinant adeno- associated viral (rAAV) vector to a blood vessel (arteriole, capillary, venule); angiogenesis |
| 01/03/2002 | US20020001574 Inserting a polynucleotide selecated from DNA, RNA containing a viral vector into a vessel having a permeable wall and increasing the permeability of the wall for a time sufficent to allow delivery of the polynucleotide to the muscle cells |
| 01/03/2002 | CA2648051A1 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| 01/03/2002 | CA2648048A1 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| 01/03/2002 | CA2648046A1 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| 01/03/2002 | CA2414077A1 Virus vector for introducing gene into renal cells |
| 01/03/2002 | CA2413768A1 Pharmaceutical compositions for angiogenic therapy |
| 01/03/2002 | CA2413543A1 Human papilloma virus treatment |
| 01/03/2002 | CA2413201A1 Treatment for cardiovascular disease |
| 01/03/2002 | CA2412637A1 Replication deficient adenoviral tnf vector |
| 01/03/2002 | CA2412612A1 Eg-vegf nucleic acids and polypeptides and methods of use |
| 01/03/2002 | CA2412256A1 Polynucleotides and polypeptides encoded thereby |
| 01/03/2002 | CA2412211A1 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| 01/03/2002 | CA2409408A1 Modulation of chromosome function by chromatin remodeling agents |
| 01/03/2002 | CA2408424A1 Use of urokinase inhibitors for the treatment and/or prevention of pulmonary hypertension and/or cardiac remodelling |
| 01/02/2002 | EP1167529A2 Vector system for introducing DNA into eucaryotic cells |
| 01/02/2002 | EP1167379A2 Immunomodulatory oligonucleotides |
| 01/02/2002 | EP1167378A2 Immunomodulatory oligonucleotides |
| 01/02/2002 | EP1167377A2 Immunomodulatory oligonucleotides |
| 01/02/2002 | EP1166775A2 Targeted liposome gene delivery |
| 01/02/2002 | EP1166102A1 Heart abnormalities in vascular endothelial growth factor b (vegf-b) deficient animals and methods relating to these heart abnormalities |
| 01/02/2002 | EP1165842A1 Lentiviral vector system for high quantity screening |
| 01/02/2002 | EP1165835A2 GENOMIC SEQUENCE OF THE $i(PURH) GENE AND $i(PURH)-RELATED BIALLELIC MARKERS |
| 01/02/2002 | EP1165830A1 Adipose-derived stem cells and lattices |
| 01/02/2002 | EP1165828A1 50 human secreted proteins |
| 01/02/2002 | EP1165827A1 45 human secreted proteins |
| 01/02/2002 | EP1165819A2 Delivery of functional protein sequences by translocating polypeptides |
| 01/02/2002 | EP1165818A2 Therapy of cancer by insect cells containing recombinant baculovirus encoding genes |
| 01/02/2002 | EP1165817A1 Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration |